Hospira Heparin without intended ACT effect

PLEASE NOTE: Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP).

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org.

3 posts / 0 new

Last post

Thu, 01/11/2024 - 08:17

Julie A DAmbrosi

Offline

Last seen: 6 days 17 hours ago

Joined: 07/22/2017 - 06:53

Hospira Heparin without intended ACT effect

We have received reports from our cath/EP lab of patients not demonstrating the intended anticoagulant effect, a therapeutic ACT, from Hospira's Heparin 10,000 units/10 ml NDC 0409-2720-31, lot HA0269, exp 2/1/2025 following administration of typical bolus doses of this product. Alternative heparin product did result in intended effect. Case reviews are underway for identifiable contributing factors to heparin resistance.

This experience has been reported to FDA and manufacturer.

Anyone else identifying similar experience?

Members Log In